Efficacy and safety of fulvestrant for treating patients with hormone receptor positive advanced breast cancer

Abstract:

Objective：To investigate the efficacy and safety of fulvestrant for treating patients with hormone receptor（HR） positive advanced breast cancer. Methods：Clinical data of 80 patients with HR positive advanced breast cancer who were treated with fulves－trant in our hospital from January 2015 to June 2016 were collected. The clinical efficacy of fulvestrant，influencing factors and ad－verse effect were evaluated. Results：The median follow-up was 6.7 months（2.0，35.6 months），median treatment cycle was 7 cycles （2，28 cycles），median progression free survival（PFS） was 9.3 months（95%CI=4.64-13.96），objective response rate（ORR） was 2.5% and clinical benefit rate（CBR） was 40.0%. COX multivariate analysis indicated that PFS was correlated with previous lines of chem-otherapy[HR=2.18（1.55，3.08），P=0.000]. Conclusion：Fulvestrant of 500 mg has a favorable efficacy in patients with HR positive advanced breast cancer，with good safety.